Cardio3 BioSciences, a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a significant patent application covering T-Cell receptor-deficient T-Cells which are engineered to express a chimeric antigen receptor.
from The Medical News http://ift.tt/1H7mXY9
from The Medical News http://ift.tt/1H7mXY9
No comments:
Post a Comment